Aligos Therapeutics
ALGS
35 hedge funds and large institutions have $27.1M invested in Aligos Therapeutics in 2025 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
15.26% more ownership
Funds ownership: 46.8% → 62.06% (+15%)
3% more funds holding
Funds holding: 34 → 35 (+1)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
58% less capital invested
Capital invested by funds: $64.5M → $27.1M (-$37.4M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$9.03M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$6.91M |
| 3 |
HCM
Heights Capital Management
San Francisco,
California
|
+$5.29M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$5.29M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.66M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.89M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.56M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.6M |
| 5 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
-$1.22M |
ALGS Hedge Fund Activity: Q1 2025 in Review
35 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2025, worth a combined $27.1M — down 58% from $64.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ALGS positions and 9 closed out — a net gain of 2 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $9.03M. The largest seller was EcoR1 Capital, cutting an estimated $3.66M.
- 35 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2025, up from 34 in Q4 2024.
- Funds reported $27.1M of Aligos Therapeutics stock for Q1 2025, down 58% quarter-over-quarter.
- 11 funds opened new Aligos Therapeutics positions in Q1 2025 and 9 closed out, a net change of +2 holders.
- The largest Aligos Therapeutics buyer in Q1 2025 was Alyeska Investment Group, an estimated $9.03M added.
- The largest Aligos Therapeutics seller in Q1 2025 was EcoR1 Capital, an estimated $3.66M sold.
Based on aggregated 13F filings for Q1 2025.